Dexmedetomidine - Hospira/Orion/Recro Pharma

Drug Profile

Dexmedetomidine - Hospira/Orion/Recro Pharma

Alternative Names: DA 9501; DEX-IN; DEX-SL; DEX-TD; Dexdor; MPV-1440; Precedex; Primadex

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Orion
  • Developer Hospira; Maruishi Pharmaceutical; Orion; Recro Pharma; Turku University Hospital
  • Class Anxiolytics; Hypnosedatives; Imidazoles; Non-opioid analgesics; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Sedation
  • Phase II Cancer pain; Pain
  • Phase I/II Subarachnoid haemorrhage
  • Discontinued Delirium; Postoperative pain

Most Recent Events

  • 15 Nov 2017 Recro Pharma initiates enrolment in a phase II trial for Pain in USA (Intranasal) (NCT03348423)
  • 27 Feb 2017 Hospira initiates enrolment in a phase I/II trial for Sedation (In infants) in USA (EudraCT2017-000407-24)
  • 21 Feb 2017 Hospira initiates enrolment in a phase III trial in Sedation (In infants, In children, In adolescents) in USA (EudraCT2017-000320-10)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top